Imara
NASDAQ: ELVNacquired by Enliven TherapeuticsCambridge, US · Founded 2016 · Delaware corporation · 5 known investors
Find your way into Imara
Acquired by Enliven Therapeutics February 2023 · terms undisclosed — ~$340M (third-party estimate, not company-confirmed) · source ↗
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion. The company combines validated biological targets with drug design and clinical strategies aimed at improving patient outcomes through precision medicine approaches.
Founders & leadership
Board
Investors · 5
Reported raises · per SEC filings
Form D private placements$140.1M disclosed across 3 of 6 rounds · 1900–2024
▶$90MraisedApr 2024 · 20 investors · PharmaceuticalsRule 506(b)
- Helen CollinsExecutive Officer
- Andrew PhillipsDirector
- Richard HeymanDirector
- Mika DerynckDirector
- Benjamin HohlExecutive Officer
- Anish PatelExecutive Officer
- Joseph P. LyssikatosExecutive Officer, Director
- Jake BauerDirector
- Rahul BallalDirector
- Rishi GuptaDirector
- Samuel KintzExecutive Officer, Director
- Offering amount
- $90M
- Amount sold
- $90M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$44.1MraisedMar 2019 · 11 investors · PharmaceuticalsRule 506(b)
- David BonitaDirector
- Christoph M. AdamsExecutive Officer
- Barbara DaltonDirector
- James G. McArthurDirector
- Rahul BallalExecutive Officer, Director
- David MottDirector
- Carl GoldfischerDirector
- Mark ChinDirector
- Mette Kirstine AggerDirector
- Sara NayeemDirector
- Offering amount
- $63M
- Amount sold
- $44.1M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$6MraisedApr 2016 · 7 investors · PharmaceuticalsRule 506(b)
- Sara NayeemDirector
- Barbara DaltonDirector
- David MottDirector
- Robert HopfnerDirector
- Mette Kirstine AggerDirector
- James G. McArthurExecutive Officer, Director
- Christoph M. AdamsExecutive Officer, Director
- Offering amount
- $31M
- Amount sold
- $6M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Imara do?
- Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion. The company combines validated biological targets with drug design and clinical strategies aimed at improving patient outcomes through precision medicine approaches.
- Who are Imara's investors?
- Imara's investors include Bay City Capital, New Enterprise Associates (NEA), RA Capital, Arix Bioscience, OrbiMed.
- How much funding has Imara raised?
- Imara has disclosed $140.1M raised across 3 of its 6 known rounds.
- Who acquired Imara?
- Imara was acquired by Enliven Therapeutics.
- Where is Imara headquartered?
- Imara is headquartered in Cambridge, US.